LEAP2 Is an Endogenous Antagonist of the Ghrelin Receptor

Xuecai Ge(NGM Biopharmaceuticals (United States)), Hong Yang(NGM Biopharmaceuticals (United States)), Maria A. Bednarek, Hadas Galon-Tilleman(NGM Biopharmaceuticals (United States)), Peirong Chen(NGM Biopharmaceuticals (United States)), Michael Chen(NGM Biopharmaceuticals (United States)), Joshua S. Lichtman(NGM Biopharmaceuticals (United States)), Yan Wang(NGM Biopharmaceuticals (United States)), Olivier Dalmas(NGM Biopharmaceuticals (United States)), Yiyuan Yin(NGM Biopharmaceuticals (United States)), Hui Tian(NGM Biopharmaceuticals (United States)), Lutz Jermutus(AstraZeneca (Germany)), Joseph Grimsby, Cristina M. Rondinone, Anish Konkar, Daniel D. Kaplan(NGM Biopharmaceuticals (United States))
Cell Metabolism
December 8, 2017
Cited by 359Open Access
Full Text

Abstract


Related Papers

No related papers found

Powered by citation graph analysis